IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.